Skip to Content
Global News Select

Roche's Columvi Meets Main Goal in Lymphoma Phase 3 Trial

By Adria Calatayud


Roche Holding said its Columvi drug helped lymphoma patients who had received at least one prior treatment live longer in a phase 3 clinical trial, meeting the primary goal of the study.

The Swiss pharmaceutical giant said Monday that Columvi, in combination with chemotherapy, showed a statistically significant improvement in overall survival for people with diffuse large B-cell lymphoma--a form of blood cancer--who had received at least one prior line of therapy and weren't candidates for transplant of their own stem cells.

Roche said safety of the drug combination appeared consistent with the known safety profiles of the individual medicines.

Data from the trial will be submitted to health authorities, the company said. Roche intends to publish more details at an upcoming medical meeting, it said.

Columvi already received approval by the U.S. Food and Drug Administration and conditional authorization from the European Commission to treat people with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of therapy, Roche said.


Write to Adria Calatayud at


(END) Dow Jones Newswires

April 15, 2024 01:39 ET (05:39 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Market Updates

Sponsor Center